French biotech firm surprises analysts with corona vaccine data

French biotech company Valneva has surprised the market with positive Covid-19 vaccine data, something one analyst welcomes, as different types of boosters may be necessary in the ongoing fight against the virus.
Photo: David Vincent/AP/Ritzau Scanpix
Photo: David Vincent/AP/Ritzau Scanpix
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

After a rollercoaster year, French biotech business Valneva is experiencing somewhat of a comeback on the Covid-19 front, after having presented promising phase III data for its Covid-19 vaccine. Investors have rewarded it by sending Valneva stock up by more than 30 percent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading